AllerGen researchers appointed to Hydra Biosciences Advisory Board

AllerGen research leader Dr. Paul O’Byrne has been appointed to the newly created Pulmonary Medical Advisory Board of Hydra Biosciences, a Massachusetts-based biopharmaceutical company that develops drugs to treat pain, inflammation, renal disease, anxiety and pulmonary disease.

Dr. O’Byrne, a respirologist, leads AllerGen’s Clinical Investigator Collaborative, a multi-centre Phase II clinical trials consortium enhancing drug discovery for allergic diseases from proof-of-concept to use in patient populations. He is also Professor and Chair of Medicine at McMaster University, and Director of the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare in Hamilton, Ontario.

Dr. Sven-Erik Dahlén, Director of the Centre for Allergy Research (CfA) of the Karolinska Institutet in Stockholm, Sweden, an AllerGen research partner, has also been appointed to the Pulmonary Medical Advisory Board.